Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society

John Christopher G. Gallagher, Bruce Ettinger, M. L S Gass, Risa Kagan, Betsy L. McClung, Michael R. McClung, James A. Simon

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Objective: The North American Menopause Society (NAMS) established a goal to create an evidence-based position statement regarding the management of postmenopausal osteoporosis. Design: NAMS followed the general principles established for evidence-based guidelines to create this document. A MEDLINE search was conducted. Clinicians and researchers acknowledged to be experts in the field of osteoporosis were enlisted to review the evidence. The NAMS Board of Trustees reviewed and approved the final document. Results: Osteoporosis, which has its highest rate of occurrence in postmenopausal women, increases the risk for fractures, including hip and spine fractures. These injuries are often associated with particularly high morbidity and mortality. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures by slowing or preventing bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to falls. The evaluation of postmenopausal women for osteoporosis risk requires the recording of a medical history, a physical examination, and diagnostic tests. Major risk factors for osteoporosis are age, genetics, lifestyle (especially nutrition), and menopausal status. Management focuses first on nonpharmacologic measures, such as a balanced diet including adequate calcium and vitamin D intakes, appropriate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, FDA-approved options are estrogens (prevention only), bisphosphonates and selective estrogen-receptor modulators (prevention and treatment), and calcitonin (treatment only). Conclusions: Management of postmenopausal osteoporosis involves identifying the potential risk for osteoporosis and osteoporotic fracture, followed by measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.

Original languageEnglish
Pages (from-to)84-101
Number of pages18
JournalMenopause
Volume9
Issue number2
StatePublished - 2002
Externally publishedYes

Fingerprint

Postmenopausal Osteoporosis
Osteoporosis
Osteoporotic Fractures
Menopause
Life Style
Selective Estrogen Receptor Modulators
Therapeutics
Trustees
Bone and Bones
Hip Fractures
Diphosphonates
Calcitonin
Smoking Cessation
Nutritional Status
Routine Diagnostic Tests
Vitamin D
MEDLINE
Physical Examination
Estrogens
Spine

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Gallagher, J. C. G., Ettinger, B., Gass, M. L. S., Kagan, R., McClung, B. L., McClung, M. R., & Simon, J. A. (2002). Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society. Menopause, 9(2), 84-101.

Management of postmenopausal osteoporosis : Position statement of the North American Menopause Society. / Gallagher, John Christopher G.; Ettinger, Bruce; Gass, M. L S; Kagan, Risa; McClung, Betsy L.; McClung, Michael R.; Simon, James A.

In: Menopause, Vol. 9, No. 2, 2002, p. 84-101.

Research output: Contribution to journalArticle

Gallagher, JCG, Ettinger, B, Gass, MLS, Kagan, R, McClung, BL, McClung, MR & Simon, JA 2002, 'Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society', Menopause, vol. 9, no. 2, pp. 84-101.
Gallagher JCG, Ettinger B, Gass MLS, Kagan R, McClung BL, McClung MR et al. Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society. Menopause. 2002;9(2):84-101.
Gallagher, John Christopher G. ; Ettinger, Bruce ; Gass, M. L S ; Kagan, Risa ; McClung, Betsy L. ; McClung, Michael R. ; Simon, James A. / Management of postmenopausal osteoporosis : Position statement of the North American Menopause Society. In: Menopause. 2002 ; Vol. 9, No. 2. pp. 84-101.
@article{616dc989c3c9454ca04468611b4cafbb,
title = "Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society",
abstract = "Objective: The North American Menopause Society (NAMS) established a goal to create an evidence-based position statement regarding the management of postmenopausal osteoporosis. Design: NAMS followed the general principles established for evidence-based guidelines to create this document. A MEDLINE search was conducted. Clinicians and researchers acknowledged to be experts in the field of osteoporosis were enlisted to review the evidence. The NAMS Board of Trustees reviewed and approved the final document. Results: Osteoporosis, which has its highest rate of occurrence in postmenopausal women, increases the risk for fractures, including hip and spine fractures. These injuries are often associated with particularly high morbidity and mortality. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures by slowing or preventing bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to falls. The evaluation of postmenopausal women for osteoporosis risk requires the recording of a medical history, a physical examination, and diagnostic tests. Major risk factors for osteoporosis are age, genetics, lifestyle (especially nutrition), and menopausal status. Management focuses first on nonpharmacologic measures, such as a balanced diet including adequate calcium and vitamin D intakes, appropriate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, FDA-approved options are estrogens (prevention only), bisphosphonates and selective estrogen-receptor modulators (prevention and treatment), and calcitonin (treatment only). Conclusions: Management of postmenopausal osteoporosis involves identifying the potential risk for osteoporosis and osteoporotic fracture, followed by measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.",
author = "Gallagher, {John Christopher G.} and Bruce Ettinger and Gass, {M. L S} and Risa Kagan and McClung, {Betsy L.} and McClung, {Michael R.} and Simon, {James A.}",
year = "2002",
language = "English",
volume = "9",
pages = "84--101",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Management of postmenopausal osteoporosis

T2 - Position statement of the North American Menopause Society

AU - Gallagher, John Christopher G.

AU - Ettinger, Bruce

AU - Gass, M. L S

AU - Kagan, Risa

AU - McClung, Betsy L.

AU - McClung, Michael R.

AU - Simon, James A.

PY - 2002

Y1 - 2002

N2 - Objective: The North American Menopause Society (NAMS) established a goal to create an evidence-based position statement regarding the management of postmenopausal osteoporosis. Design: NAMS followed the general principles established for evidence-based guidelines to create this document. A MEDLINE search was conducted. Clinicians and researchers acknowledged to be experts in the field of osteoporosis were enlisted to review the evidence. The NAMS Board of Trustees reviewed and approved the final document. Results: Osteoporosis, which has its highest rate of occurrence in postmenopausal women, increases the risk for fractures, including hip and spine fractures. These injuries are often associated with particularly high morbidity and mortality. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures by slowing or preventing bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to falls. The evaluation of postmenopausal women for osteoporosis risk requires the recording of a medical history, a physical examination, and diagnostic tests. Major risk factors for osteoporosis are age, genetics, lifestyle (especially nutrition), and menopausal status. Management focuses first on nonpharmacologic measures, such as a balanced diet including adequate calcium and vitamin D intakes, appropriate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, FDA-approved options are estrogens (prevention only), bisphosphonates and selective estrogen-receptor modulators (prevention and treatment), and calcitonin (treatment only). Conclusions: Management of postmenopausal osteoporosis involves identifying the potential risk for osteoporosis and osteoporotic fracture, followed by measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.

AB - Objective: The North American Menopause Society (NAMS) established a goal to create an evidence-based position statement regarding the management of postmenopausal osteoporosis. Design: NAMS followed the general principles established for evidence-based guidelines to create this document. A MEDLINE search was conducted. Clinicians and researchers acknowledged to be experts in the field of osteoporosis were enlisted to review the evidence. The NAMS Board of Trustees reviewed and approved the final document. Results: Osteoporosis, which has its highest rate of occurrence in postmenopausal women, increases the risk for fractures, including hip and spine fractures. These injuries are often associated with particularly high morbidity and mortality. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures by slowing or preventing bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to falls. The evaluation of postmenopausal women for osteoporosis risk requires the recording of a medical history, a physical examination, and diagnostic tests. Major risk factors for osteoporosis are age, genetics, lifestyle (especially nutrition), and menopausal status. Management focuses first on nonpharmacologic measures, such as a balanced diet including adequate calcium and vitamin D intakes, appropriate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, FDA-approved options are estrogens (prevention only), bisphosphonates and selective estrogen-receptor modulators (prevention and treatment), and calcitonin (treatment only). Conclusions: Management of postmenopausal osteoporosis involves identifying the potential risk for osteoporosis and osteoporotic fracture, followed by measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036190678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036190678&partnerID=8YFLogxK

M3 - Article

C2 - 11875327

AN - SCOPUS:0036190678

VL - 9

SP - 84

EP - 101

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 2

ER -